Advertisement

Treatment of Indolent Adult T-cell Leukemia/Lymphoma (ATL)

  • Kenji Ishitsuka
Chapter

Abstract

Indolent adult T-cell leukemia-lymphoma (ATL) is consisted of a smoldering type and a favorable chronic type. The 4-year overall survival (OS) of smoldering and favorable ATL has been found to be 52% and 60%, respectively, by a Japanese retrospective survey. However, no solid information has been acquired from prospective trials in determining an appropriate standard of care, although an International Consensus Meeting has recommended considering combination treatment of interferon-α and zidovudine or watchful waiting if patients are symptomatic, or watchful waiting alone if patients are asymptomatic. In addition, local therapy such as skin-directed therapy using topical steroids, ultraviolet B treatment, psoralen photochemotherapy, electron beam therapy, radiation therapy, or single-agent chemotherapy by etoposide or sobuzoxane has been incorporated in practice with indeterminate survival benefit. The optimal treatment for indolent ATL has not yet been determined; thus, conducting prospective studies in this cohort of patients is of great importance.

Keywords

Indolent ATL Watchful waiting IFN/AZT 

References

  1. 1.
    Bazarbachi A, Plumelle Y, Ramos CJ, Tortevoye P, Otrock Z, Taylor C, Gessain A, Harrington W, Panelatti G, Hermine O. Meta-analysis on the use of Zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, Yamochi T, Nakashima M, Kobayashi S, Tanaka Y, Iwanaga M, Utsunomiya A, Uchimaru K, Yamagishi M, Watanabe T. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790–802.CrossRefPubMedGoogle Scholar
  3. 3.
    Gill PS, Harrington Jr W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Gabral L, Allen S, Kornblau S, Pike MC, Levine AM. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;113:779–84.Google Scholar
  4. 4.
    Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the cute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Ichimaru M, Kamihira S, Moriuchi Y, Kuraishi Y, Usui N, Toki H, Okabe Y, Shibuya T, Umei T. Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia. Jpn J Cancer Chemother. 1988;15:2975–81. (In Japanese)Google Scholar
  7. 7.
    Ishitsuka K, Fukushima T, Tsukasaki K, Tobinai K. Is Zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma? J Clin Oncol. 2010;28:e765.CrossRefPubMedGoogle Scholar
  8. 8.
    Ishitsuka K, Tsukasaki K, Tamura K. Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma. Drugs Today (Barc). 2011;47(8):615–23.Google Scholar
  9. 9.
    Kamihira S, Soda H, Kinoshita K, Ichimaru M. Effect of human lymphoblast interferon in adult T-cell leukemia and non-Hodgkin’s lymphoma. Jpn J Cancer Chemother. 1983;10:2188–93. (In Japanese)Google Scholar
  10. 10.
    Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, Ishii R, Muto S, Kotani S, Watatani Y, Takeda J, Sanada M, Tanaka H, Suzuki H, Sato Y, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Iwanaga M, Ma G, Nosaka K, Hishizawa M, Itonaga H, Imaizumi Y, Munakata W, Ogasawara H, Sato T, Sasai K, Muramoto K, Penova M, Kawaguchi T, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Nakamaki T, Ishiyama K, Miyawaki S, Yoon SS, Tobinai K, Miyazaki Y, Takaori-Kondo A, Matsuda F, Takeuchi K, Nureki O, Aburatani H, Watanabe T, Shibata T, Matsuoka M, Miyano S, Shimoda K, Ogawa S. Integrated molecular analysis of adult T-cell leukemia/lymphoma. Nat Genet. 2015;47:1304–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Kimura K. Cooperative Study Group of Ro 22-8181 in Japan. Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in hematological malignancies. Jpn J Cancer Chemother. 1985;12:928–35. (In Japanese)Google Scholar
  12. 12.
    Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Ymashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, Shimokawa M, Kawai K, Suzumiya J, Tamura K. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Kochour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rahim Rezaee SA, Yazdi MT, Shirdel A, de The H, Hermine O, Farid R, Bazarbachi A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113:6528–32.CrossRefGoogle Scholar
  14. 14.
    Matsumura M, Yoneyama A, Nakamura T, Higashihara M, Yotami Y, Tanabe A, Ohashi T, Oka H, Nakahara K. A first case of complete remission of β-interferon sensitive adult T-cell leukemia. Eur J Haematol. 1987;39:282–7.Google Scholar
  15. 15.
    Matutes E, Taylor GP, Gavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113:779–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-cell leukemia. Oxford: Oxford University Press; 1994. p. 221–37.Google Scholar
  18. 18.
    Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, Tokura Y, Nozaki K, Isutsu K, Suzuki R, Setoyama M, Nagatani T, Koga H, Tani M, Iwatsuki K. Guideline for the management of cutaneous lymphoma (2011): a consensus statement by the Japanese Skin Cancer Society – Lymphoma Study Group. J Dermatol. 2013;40:2–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Simone 2nd CBII, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood. 2012;120:1816–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tsukasaki K, Hermine O, Bazarbachi A, Tatner L, Ramos JC, Harrington Jr W, O’Mahony D, Janik JE, Bitterncourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yamada Y. High-risk aggressive lymphoma (ATL). Rinsho Ketsueki. 2001;42:293–8. (In Japanese)Google Scholar
  23. 23.
    Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak ML, Spira TJ, Gill P. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). Ann Intern Med. 1989;111(11):871–5.Google Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  1. 1.Division of Hematology and Immunology, Center for Chronic Viral Disease, Graduate School of Medical and Dental SciencesKagoshima UniversityKagoshimaJapan

Personalised recommendations